JP2005527570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527570A5 JP2005527570A5 JP2003581716A JP2003581716A JP2005527570A5 JP 2005527570 A5 JP2005527570 A5 JP 2005527570A5 JP 2003581716 A JP2003581716 A JP 2003581716A JP 2003581716 A JP2003581716 A JP 2003581716A JP 2005527570 A5 JP2005527570 A5 JP 2005527570A5
- Authority
- JP
- Japan
- Prior art keywords
- antithrombin iii
- composition
- composition according
- lung injury
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (13)
- アンチトロンビンIIIを含有し、吸入投与されることを特徴とする、急性肺損傷を治療するための組成物。
- 肺損傷が感染性急性肺損傷であることを特徴とする請求項１記載の組成物。
- 肺損傷が急性呼吸窮迫症候群であることを特徴とする請求項１記載の組成物。
- 肺損傷が、ウイルス物質への曝露によって生じたものであることを特徴とする請求項１記載の組成物。
- 前記ウイルス物質が緑膿菌であることを特徴とする請求項４記載の組成物。
- 肺損傷が、煙およびアスベストの１つ以上によって生じたものであることを特徴とする請求項１記載の組成物。
- 超音波ネブライザーを用いて投与されることを特徴とする請求項１記載の組成物。
- アンチトロンビンIIIが、血漿由来アンチトロンビンIIIであることを特徴とする請求項１記載の組成物。
- アンチトロンビンIIIが、組み換えによって製造されたアンチトロンビンIIIであることを特徴とする請求項１記載の組成物。
- 組み換えによって製造されたアンチトロンビンIIIが、遺伝子導入によって製造されたアンチトロンビンIIIであることを特徴とする請求項９記載の組成物。
- １単位用量より多くが対象に投与されることを特徴とする請求項１記載の組成物。
- 単位用量が、約１０〜３００Ｕ／ｋｇのアンチトロンビンIIIを含有することを特徴とする請求項１記載の組成物。
- 単位用量が、約２５〜１２５Ｕ／ｋｇのアンチトロンビンIIIを含有することを特徴とする請求項１記載の組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36899702P | 2002-04-01 | 2002-04-01 | |
| PCT/US2003/009053 WO2003084476A2 (en) | 2002-04-01 | 2003-03-25 | Treatment of lung disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011176604A Division JP2011225625A (ja) | 2002-04-01 | 2011-08-12 | 肺障害の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527570A JP2005527570A (ja) | 2005-09-15 |
| JP2005527570A5 true JP2005527570A5 (ja) | 2006-05-25 |
Family
ID=29420316
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003581716A Pending JP2005527570A (ja) | 2002-04-01 | 2003-03-25 | 肺障害の治療 |
| JP2011176604A Withdrawn JP2011225625A (ja) | 2002-04-01 | 2011-08-12 | 肺障害の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011176604A Withdrawn JP2011225625A (ja) | 2002-04-01 | 2011-08-12 | 肺障害の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090221475A9 (ja) |
| EP (1) | EP1494696A4 (ja) |
| JP (2) | JP2005527570A (ja) |
| KR (2) | KR20040105838A (ja) |
| CN (1) | CN100384469C (ja) |
| AU (3) | AU2003233428B2 (ja) |
| CA (1) | CA2480790A1 (ja) |
| IL (2) | IL164078A0 (ja) |
| NZ (1) | NZ535487A (ja) |
| WO (1) | WO2003084476A2 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050169908A1 (en) * | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
| US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| US20050245444A1 (en) * | 2004-04-30 | 2005-11-03 | Yann Echelard | Method of using recombinant human antithrombin for neurocognitive disorders |
| US20060121004A1 (en) * | 2004-12-07 | 2006-06-08 | Yann Echelard | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin |
| WO2012051339A2 (en) * | 2010-10-12 | 2012-04-19 | Vetgel Technologies | Methods and compositions for treating respiratory conditions using platelet enriched plasma |
| SG191781A1 (en) | 2010-12-30 | 2013-08-30 | Lab Francais Du Fractionnement | Glycols as pathogen inactivating agents |
| EP2956003A2 (en) | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EP3594231A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| WO2015001277A1 (fr) | 2013-07-05 | 2015-01-08 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Matrice de chromatographie d'affinité |
| WO2015192020A1 (en) | 2014-06-13 | 2015-12-17 | Children's Medical Center Corporation | Products and methods to isolate mitochondria |
| JP2022529262A (ja) * | 2019-04-15 | 2022-06-20 | チルドレンズ メディカル センター コーポレイション | ミトコンドリアを含むエアロゾル化組成物及びその使用方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08782B2 (ja) * | 1986-11-22 | 1996-01-10 | 株式会社ミドリ十字 | 抗炎症剤 |
| DE4117078A1 (de) * | 1991-05-25 | 1992-11-26 | Boehringer Ingelheim Kg | Verfahren zur herstellung therapeutisch anwendbarer aerosole |
| JPH06256213A (ja) * | 1993-03-03 | 1994-09-13 | Green Cross Corp:The | ヒト由来アンチトロンビン−ｉｉｉの医薬用途 |
| US6127347A (en) * | 1994-01-12 | 2000-10-03 | Univ Michigan | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
| US6355626B1 (en) * | 1994-05-13 | 2002-03-12 | The Trustees Of The University Of Pennsylvania | Antithrombin agents in treatment of asthma |
| US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US6562781B1 (en) * | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
| JPH09176040A (ja) * | 1995-12-27 | 1997-07-08 | Green Cross Corp:The | ヘパリンコファクターｉｉの医薬用途 |
| US6063593A (en) * | 1996-11-12 | 2000-05-16 | University Of Southern California University Park Campus | TGFβ1 responsive bone marrow derived cells to express a recombinant protein |
| US6124257A (en) * | 1997-08-28 | 2000-09-26 | Lezdey; John | Method of treatment |
| US6838428B2 (en) * | 1998-10-20 | 2005-01-04 | Children's Hospital Medical Center | Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| CA2347248C (en) * | 1998-10-20 | 2011-09-20 | Children's Hospital Medical Center | Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| DE10045047A1 (de) * | 2000-09-12 | 2002-03-21 | Beate Kehrel | Arzneimittel enthaltend aktiviertes Antithrombin III |
| AU2440802A (en) * | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides |
| DE10132307A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
| US20050169908A1 (en) * | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
| US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
-
2003
- 2003-03-25 CA CA002480790A patent/CA2480790A1/en not_active Abandoned
- 2003-03-25 EP EP03728277A patent/EP1494696A4/en not_active Withdrawn
- 2003-03-25 IL IL16407803A patent/IL164078A0/xx active IP Right Grant
- 2003-03-25 CN CNB03807463XA patent/CN100384469C/zh not_active Expired - Fee Related
- 2003-03-25 JP JP2003581716A patent/JP2005527570A/ja active Pending
- 2003-03-25 KR KR10-2004-7015636A patent/KR20040105838A/ko not_active Application Discontinuation
- 2003-03-25 AU AU2003233428A patent/AU2003233428B2/en not_active Revoked
- 2003-03-25 WO PCT/US2003/009053 patent/WO2003084476A2/en active Application Filing
- 2003-03-25 KR KR1020107022448A patent/KR20100117148A/ko active Application Filing
- 2003-03-25 US US10/396,855 patent/US20090221475A9/en not_active Abandoned
- 2003-03-25 NZ NZ535487A patent/NZ535487A/en not_active IP Right Cessation
-
2004
- 2004-09-14 IL IL164078A patent/IL164078A/en not_active IP Right Cessation
-
2008
- 2008-10-31 AU AU2008243077A patent/AU2008243077A1/en not_active Withdrawn
-
2011
- 2011-08-12 JP JP2011176604A patent/JP2011225625A/ja not_active Withdrawn
- 2011-10-10 AU AU2011236070A patent/AU2011236070A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007518801A5 (ja) | ||
| JP2005527570A5 (ja) | ||
| CY1108326T1 (el) | ΝΕΟΣ ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ ΚΑΙ β ΜΙΜΗΤΙΚΩΝ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΑΝΑΠΝΕΥΣΤΙΚΩΝ ΑΣΘΕΝΕΙΩΝ | |
| DK2156840T3 (da) | Anvendelse af mometasonfuroat til behandling af luftvejs- og lungesygdomme | |
| JP2007514005A5 (ja) | ||
| JP2003526626A5 (ja) | ||
| NO20024708D0 (no) | Behandling av respiratoriske sykdommer | |
| ATE466591T1 (de) | Interferon-beta zur antiviralen therapie für atemwegserkrankungen | |
| JP2008533072A5 (ja) | ||
| CY1108420T1 (el) | Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη | |
| EA200701077A1 (ru) | Применение конъюгатов липидов при лечении заболеваний | |
| JP2020516689A5 (ja) | ||
| FRIEDE et al. | Symptomatic pulmonary disease in arc welders | |
| JP2002345966A (ja) | 吸入器への呼気逆流防止装置 | |
| ATE276761T1 (de) | Vorbeugung von typ-1 diabetes und anderen nicht- polio enteroviren | |
| ATE364419T1 (de) | Inhalator | |
| JP2003528925A5 (ja) | ||
| JP2006212370A (ja) | 呼吸用空気濾過器 | |
| Ozturk et al. | Role of SARS-CoV-2 in asthma exacerbations | |
| JP3232632U (ja) | 呼気ウイルス不活化システム | |
| Misra | A short review on important drugs under clinical trial against Covid-19 | |
| Rajesh et al. | T‑Piece for COVID‑19 Patients: Innovation in a Time of Crisis | |
| RU2002114535A (ru) | Способ лечения бронхиальной астмы у детей в приступном периоде | |
| Samarasinghe et al. | Eosinophils and Macrophages Direct Allergic Host Responses During Synergistic Viral-Bacterial Infections | |
| MX2023002702A (es) | Composicion farmaceutica que comprende cloroquina y usos de esta. |